This is a Validated Antibody Database (VAD) review about human Tim 3, based on 45 published articles (read how Labome selects the articles), using Tim 3 antibody in all methods. It is aimed to help Labome visitors find the most suited Tim 3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Tim 3 synonym: CD366; HAVcr-2; KIM-3; SPTCL; TIM3; TIMD-3; TIMD3; Tim-3

BioLegend
mouse monoclonal (F38-2E2)
  • other; mouse
BioLegend Tim 3 antibody (BioLegend, F38-2E2) was used in other on mouse samples . Nat Commun (2020) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig 5a
BioLegend Tim 3 antibody (BioLegend, 345006) was used in flow cytometry on human samples (fig 5a). elife (2020) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig 6b, 6c
BioLegend Tim 3 antibody (BioLegend, F38-2E2) was used in flow cytometry on human samples (fig 6b, 6c). Oncoimmunology (2020) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; fig 4d
BioLegend Tim 3 antibody (Biolegend, F38-2E2) was used in flow cytometry on human samples (fig 4d). J Immunother Cancer (2020) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; fig e1a
BioLegend Tim 3 antibody (BioLegend, F38-2E2) was used in flow cytometry on human samples (fig e1a). Nature (2019) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; mouse; loading ...; fig 5a
BioLegend Tim 3 antibody (Biolegend, 345012) was used in flow cytometry on mouse samples (fig 5a). J Immunother Cancer (2019) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig 5a
BioLegend Tim 3 antibody (BioLegend, F38- 2E2) was used in flow cytometry on human samples (fig 5a). Front Immunol (2019) ncbi
mouse monoclonal (F38-2E2)
  • mass cytometry; human; loading ...; fig 2b
BioLegend Tim 3 antibody (Biolegend, 345035) was used in mass cytometry on human samples (fig 2b). Cell (2019) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; mouse; loading ...; fig ex2g
BioLegend Tim 3 antibody (Biolegend, F38-2E2) was used in flow cytometry on mouse samples (fig ex2g). Nature (2019) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig s1a
BioLegend Tim 3 antibody (Biolegend, 345006) was used in flow cytometry on human samples (fig s1a). J Clin Invest (2019) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig s2b
BioLegend Tim 3 antibody (Biolegend, F38-2E2) was used in flow cytometry on human samples (fig s2b). Nat Med (2019) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig s3a
BioLegend Tim 3 antibody (Biolegend, F38-2E2) was used in flow cytometry on human samples (fig s3a). Cancer (2019) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; fig s2e
BioLegend Tim 3 antibody (BioLegend, 345012) was used in flow cytometry on human samples (fig s2e). Cell (2018) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig 2
BioLegend Tim 3 antibody (Biolegend, F38-2E2) was used in flow cytometry on human samples (fig 2). Biol Blood Marrow Transplant (2018) ncbi
mouse monoclonal (F38-2E2)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, BioLegend Tim 3 antibody (BioLegend, F38-2E2) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (F38-2E2)
  • mass cytometry; human; fig s8
BioLegend Tim 3 antibody (BioLegend, 345002) was used in mass cytometry on human samples (fig s8). Nature (2017) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; mouse; loading ...
In order to assess the effects of targeting the chimeric antigen receptors to the TRAC locus, BioLegend Tim 3 antibody (Biolegend, 345032) was used in flow cytometry on mouse samples . Nature (2017) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig 2b,2c
In order to elucidate the interaction between tumor-associated and -infiltrating lymphocytes in ovarian cancer, BioLegend Tim 3 antibody (Biolegend, 345011) was used in flow cytometry on human samples (fig 2b,2c). Oncoimmunology (2017) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig 1a
In order to study the restoration of immune function in chronic HIV infection, BioLegend Tim 3 antibody (Biolegend, F38-2E2) was used in flow cytometry on human samples (fig 1a). J Clin Invest (2017) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig 6b
In order to study the role of PD-1 and Tim-3 crosstalk in the regulation of antitumor T cell responses, BioLegend Tim 3 antibody (Biolegend, 345007) was used in flow cytometry on human samples (fig 6b). Oncoimmunology (2016) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...
In order to establish the T Cell receptor-inducible costimulator as a promising target for direct T regulatory cell-targeting therapeutic agents for gastric cancer, BioLegend Tim 3 antibody (BioLegend, F38-2E2) was used in flow cytometry on human samples . Int J Cancer (2017) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; fig s9b
In order to explore the role of exhausted CD8 positive CXCR5 positive T cells in mice chronically infected with lymphocytic choriomeningitis virus, BioLegend Tim 3 antibody (Biolegend, F38-2E2) was used in flow cytometry on human samples (fig s9b). Nature (2016) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; fig 1
In order to test if CD4 positive T cells expressing immune checkpoint molecules are enriched in HIV-infected cells in patients receiving antiretroviral therapy, BioLegend Tim 3 antibody (Biolegend, 345006) was used in flow cytometry on human samples (fig 1). PLoS Pathog (2016) ncbi
mouse monoclonal (F38-2E2)
BioLegend Tim 3 antibody (BioLegend, 345006) was used . EMBO Mol Med (2016) ncbi
mouse monoclonal (F38-2E2)
  • blocking or activating experiments; human
BioLegend Tim 3 antibody (Biolegend, F38-2E2) was used in blocking or activating experiments on human samples . Cell Death Dis (2014) ncbi
mouse monoclonal (F38-2E2)
BioLegend Tim 3 antibody (Biolegend, clone F38-2e2) was used . PLoS ONE (2014) ncbi
R&D Systems
rat monoclonal (344823)
  • flow cytometry; human; loading ...; fig s1a
R&D Systems Tim 3 antibody (R&D Systems, 344823) was used in flow cytometry on human samples (fig s1a). J Immunol (2018) ncbi
domestic goat polyclonal
  • western blot; human; loading ...; fig 6a
R&D Systems Tim 3 antibody (R&D, AF2365) was used in western blot on human samples (fig 6a). J Virol (2017) ncbi
rat monoclonal (344823)
  • flow cytometry; human; loading ...; fig 6a
R&D Systems Tim 3 antibody (R&D Systems, 344823) was used in flow cytometry on human samples (fig 6a). J Clin Invest (2016) ncbi
rat monoclonal (344801)
  • blocking or activating experiments; human; fig 3a
R&D Systems Tim 3 antibody (R&D Systems, 344801) was used in blocking or activating experiments on human samples (fig 3a). PLoS Pathog (2016) ncbi
rat monoclonal (344823)
  • flow cytometry; human; fig s5
In order to assess arming of MAIT cell cytolytic antimicrobial activity and induction by IL-7 and faulty in HIV-1 infection, R&D Systems Tim 3 antibody (R&D systems, 344823) was used in flow cytometry on human samples (fig s5). PLoS Pathog (2015) ncbi
rat monoclonal (344823)
  • flow cytometry; human; fig 4
R&D Systems Tim 3 antibody (R&D Systems, 344823) was used in flow cytometry on human samples (fig 4). Cancer Immunol Immunother (2015) ncbi
rat monoclonal (344823)
  • flow cytometry; human; fig 3
R&D Systems Tim 3 antibody (R&D Systems, 344823) was used in flow cytometry on human samples (fig 3). J Hematol Oncol (2015) ncbi
rat monoclonal (344823)
  • flow cytometry; human; loading ...; fig S2,S3
In order to look at patterns of S. Typhi-specific modulation of the homing potential of circulating Treg in patients with typhoid compared to healthy individuals, R&D Systems Tim 3 antibody (R&D, 344823) was used in flow cytometry on human samples (fig S2,S3). PLoS Pathog (2015) ncbi
rat monoclonal (344823)
  • flow cytometry; human; fig 1
In order to describe the phenotype and functional potential of metastatic differentiated thyroid cancer-associated PD-1 positive T cells, R&D Systems Tim 3 antibody (R&D systems, 344823) was used in flow cytometry on human samples (fig 1). Cancer Immunol Res (2015) ncbi
domestic goat polyclonal
R&D Systems Tim 3 antibody (R&D Systems, AF2365) was used . J Virol (2015) ncbi
rat monoclonal (344823)
  • flow cytometry; human
  • ELISA; human
R&D Systems Tim 3 antibody (R&D Systems, 344823) was used in flow cytometry on human samples and in ELISA on human samples . J Virol (2015) ncbi
rat monoclonal (344823)
  • flow cytometry; rhesus macaque
R&D Systems Tim 3 antibody (R&D Systems, 344823) was used in flow cytometry on rhesus macaque samples . J Immunol (2014) ncbi
rat monoclonal (344823)
  • immunocytochemistry; human
R&D Systems Tim 3 antibody (R&D systems, 344823) was used in immunocytochemistry on human samples . Eur J Immunol (2014) ncbi
Invitrogen
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...; fig 4b
Invitrogen Tim 3 antibody (eBioscience, F38-2E2) was used in flow cytometry on human samples (fig 4b). BMC Immunol (2020) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; 1:100; loading ...
Invitrogen Tim 3 antibody (eBioscience, F38-2E2) was used in flow cytometry on human samples at 1:100. Nature (2018) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human
In order to characterize activated T cells in joint tissue from patients with rheumatoid arthritis, Invitrogen Tim 3 antibody (eBioscience, F38-2E2) was used in flow cytometry on human samples . Nature (2017) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; fig 6
Invitrogen Tim 3 antibody (eBioscience, F38-2E2) was used in flow cytometry on human samples (fig 6). PLoS Pathog (2016) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; fig 1
Invitrogen Tim 3 antibody (eBiosciences, F38-2E2) was used in flow cytometry on human samples (fig 1). Oncoimmunology (2016) ncbi
mouse monoclonal (F38-2E2)
  • flow cytometry; human; loading ...
In order to examine the effects of immunosuppressive agents on Polyomavirus BKV-specific T cells, Invitrogen Tim 3 antibody (eBioscience, F38-2E2) was used in flow cytometry on human samples . Kidney Int (2015) ncbi
Abcam
domestic rabbit polyclonal
  • western blot; mouse; loading ...; fig 4h
Abcam Tim 3 antibody (Abcam, ab185703) was used in western blot on mouse samples (fig 4h). elife (2018) ncbi
Articles Reviewed
  1. Tseng H, Xiong W, Badeti S, Yang Y, Ma M, Liu T, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11:4810 pubmed publisher
  2. Bhattacharya P, Ellegård R, Khalid M, Svanberg C, Govender M, Keita A, et al. Complement opsonization of HIV affects primary infection of human colorectal mucosa and subsequent activation of T cells. elife. 2020;9: pubmed publisher
  3. Liu G, Yu Y, Feng F, Zhu P, Zhang H, Zhang D, et al. Human CD8+CD28- T suppressor cells expanded by common gamma chain (γc) cytokines retain steady allospecific suppressive capacity in vivo. BMC Immunol. 2020;21:23 pubmed publisher
  4. Seitz C, Schroeder S, Knopf P, Krahl A, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9:1683345 pubmed publisher
  5. Marotte L, Simon S, Vignard V, Dupré E, Gantier M, Cruard J, et al. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes. J Immunother Cancer. 2020;8: pubmed publisher
  6. Lynn R, Weber E, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293-300 pubmed publisher
  7. Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, et al. PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019;7:209 pubmed publisher
  8. Lim S, Kim J, Jeon S, Shin M, Kwon J, Kim T, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496 pubmed publisher
  9. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  10. Hamieh M, Dobrin A, Cabriolu A, van der Stegen S, Giavridis T, Mansilla Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568:112-116 pubmed publisher
  11. Finney O, Brakke H, Rawlings Rhea S, Hicks R, Doolittle D, López M, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129:2123-2132 pubmed publisher
  12. Scheper W, Kelderman S, Fanchi L, Linnemann C, Bendle G, de Rooij M, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25:89-94 pubmed publisher
  13. Williams P, Basu S, Garcia Manero G, Hourigan C, Oetjen K, Cortes J, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481 pubmed publisher
  14. Zhu H, Zhang L, Wu Y, Dong B, Guo W, Wang M, et al. T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1. elife. 2018;7: pubmed publisher
  15. Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605-609 pubmed publisher
  16. Gee M, Han A, Lofgren S, Beausang J, Mendoza J, Birnbaum M, et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell. 2018;172:549-563.e16 pubmed publisher
  17. Wang C, Edilova M, Wagar L, Mujib S, Singer M, Bernard N, et al. Effect of IL-7 Therapy on Phospho-Ribosomal Protein S6 and TRAF1 Expression in HIV-Specific CD8 T Cells in Patients Receiving Antiretroviral Therapy. J Immunol. 2018;200:558-564 pubmed publisher
  18. Hutten T, Norde W, Woestenenk R, Wang R, Maas F, Kester M, et al. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018;24:666-677 pubmed publisher
  19. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  20. Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728-732 pubmed publisher
  21. Eyquem J, Mansilla Soto J, Giavridis T, van der Stegen S, Hamieh M, Cunanan K, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113-117 pubmed publisher
  22. Huang R, Francois A, McGray A, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 pubmed publisher
  23. Rao D, Gurish M, Marshall J, Slowikowski K, Fonseka C, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110-114 pubmed publisher
  24. Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J Clin Invest. 2017;127:260-268 pubmed publisher
  25. Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
  26. Wang J, Qiao L, Hou Z, Luo G. TIM-1 Promotes Hepatitis C Virus Cell Attachment and Infection. J Virol. 2017;91: pubmed publisher
  27. Nagase H, Takeoka T, Urakawa S, Morimoto Okazawa A, Kawashima A, Iwahori K, et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686-695 pubmed publisher
  28. Pachnio A, Ciáurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016;12:e1005832 pubmed publisher
  29. He R, Hou S, Liu C, Zhang A, Bai Q, Han M, et al. Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature. 2016;537:412-428 pubmed publisher
  30. Cherkassky L, Morello A, Villena Vargas J, Feng Y, Dimitrov D, Jones D, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130-44 pubmed publisher
  31. Fromentin R, Bakeman W, Lawani M, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016;12:e1005761 pubmed publisher
  32. Abdel Mohsen M, Chavez L, Tandon R, Chew G, Deng X, Danesh A, et al. Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Pathog. 2016;12:e1005677 pubmed publisher
  33. Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Mol Med. 2016;8:702-11 pubmed publisher
  34. Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, et al. PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology. 2016;5:e1104448 pubmed
  35. Leeansyah E, Svärd J, Dias J, Buggert M, Nyström J, Quigley M, et al. Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection. PLoS Pathog. 2015;11:e1005072 pubmed publisher
  36. Japp A, Kursunel M, Meier S, Mälzer J, Li X, Rahman N, et al. Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression. Cancer Immunol Immunother. 2015;64:1487-94 pubmed publisher
  37. Weist B, Wehler P, El Ahmad L, Schmueck Henneresse M, Millward J, Nienen M, et al. A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients. Kidney Int. 2015;88:1293-1303 pubmed publisher
  38. Schnorfeil F, Lichtenegger F, Emmerig K, Schlueter M, Neitz J, Draenert R, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93 pubmed publisher
  39. McArthur M, Fresnay S, Magder L, Darton T, Jones C, Waddington C, et al. Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathog. 2015;11:e1004914 pubmed publisher
  40. Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
  41. Clayton K, Douglas Vail M, Nur Ur Rahman A, Medcalf K, Xie I, Chew G, et al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J Virol. 2015;89:3723-36 pubmed publisher
  42. Ramello M, Tosello Boari J, Canale F, Mena H, Negrotto S, Gastman B, et al. Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L. Cell Death Dis. 2014;5:e1507 pubmed publisher
  43. Fujita T, Burwitz B, Chew G, Reed J, Pathak R, Seger E, et al. Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques. J Immunol. 2014;193:5576-83 pubmed publisher
  44. Gautron A, Dominguez Villar M, de Marcken M, Hafler D. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703-2711 pubmed publisher
  45. Poonia B, Pauza C. Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy. PLoS ONE. 2014;9:e88884 pubmed publisher